

Please be sure to complete the following:

Company name: XOLTAR \* Website: www.xoltar.com \*

CEO name: Asaf Shiloni\*

Select a CATEGORY: Health IT/Digital \*

Select up to two SESSIONS per abstract from the list below \*

- Illuminating the Path; Innovations and Challenges in Eye Care

You may delete the section instructions, leaving only the bolded bullet title  
Answers below should not exceed 60 words per question:

- **Executive Summary**  
XOLTAR develops AI agents that emulate care management support for chronic patients through treatment journeys. Having raised \$1.3M, our management combines Intel-acquired AI expertise with behavioral psychology specialists. Currently partnered with Bayer, Novartis, and multiple providers, we've promoted behavioral change across thousands of patients in various therapeutic areas, including eye care, delivering scalable patient support with rich data insights.
- **Core Technology**  
XOLTAR's core technology features a trillion-parameter cascade model architecture delivering AI-guided video conversations with 95% protocol alignment while maintaining natural patient interaction. Our patent-pending system requires zero training data and seamlessly integrates evidence-based treatments. Unlike competitors' resolution-driven approach, our relationship-driven AI builds patient trust, fostering behavior change while meeting healthcare AI regulations with full transparency and adaptability to customer protocols.
- **Product Profile**  
XOLTAR's AI companions currently support patients across cancer, macular degeneration, smoking cessation, and chronic conditions with proven results. Our product roadmap includes Alzheimer's, GLP-1 support, and rare diseases for 2025. With partnerships in development for these areas, we target massive markets including 2M annual cancer cases, 30M future GLP-1 users, and 20M macular degeneration patients in the US alone.
- **Business Strategy**  
XOLTAR employs a tiered SaaS licensing model based on patient volume. Short-term revenue derives from pharma and patient support collaborations, while long-term growth focuses on expansion within existing pharma partnerships across therapeutic areas and geographies. Initially US-market focused, our AI companion platform strategically targets high-value conditions while exploring selective international opportunities for scalable, sustainable revenue growth.
- **What's Next?**  
We plan to enhance our AI companions, support additional languages, and provide advanced behavioral analytics while conducting clinical validation

studies comparing AI to human interventions. We're expanding our US sales team to accelerate pharma partnerships alongside strategic R&D growth. Our upcoming \$5M funding round will fuel these initiatives, scaling our proven technology across additional therapeutic areas and international markets.